Immunohistochemistry Collagen VII antibody [LH7.2] Mouse Human

Get tips on using siGENOME Human RAB5A (5868) siRNA - SMARTpool to perform siRNA / miRNA gene silencing Human - BT-20 Rab5a

Get tips on using siGENOME Human ATG7 (10533) siRNA - SMARTpool to perform siRNA / miRNA gene silencing Human - LN-18 ATG-7

Get tips on using siGENOME Human MAPKAPK2 (9261) siRNA - SMARTpool to perform siRNA / miRNA gene silencing Human - LN-18 MK2/MAPKAPK2

Get tips on using siGENOME Human RIPK3 (11035) siRNA - SMARTpool to perform siRNA / miRNA gene silencing Human - LN-18 RIP3/RIPK3

Get tips on using siGENOME Human AP1G1 (164) siRNA - SMARTpool to perform siRNA / miRNA gene silencing Human - HeLa γ1-adaptin/AP1G1

Get tips on using siGENOME Human CHUK (1147) siRNA - SMARTpool to perform siRNA / miRNA gene silencing Human - PANC-1 IKKα/CHUK

Get tips on using siGENOME Human IKBKB (3551) siRNA - SMARTpool to perform siRNA / miRNA gene silencing Human - PANC-1 IKKβ/IKBKB

Get tips on using siGENOME Human GSK3A (2931) siRNA - SMARTpool to perform siRNA / miRNA gene silencing Human - PANC-1 GSK-3α

Get tips on using ProcartaPlex Human Cytokine Panel 1B, 25 plex to perform ELISA (kit) Human Serum Cytokine measurements (Multiplex assay) - -NA- Human -NA-

Short hairpin or small hairpin RNA (shRNA) is artificial RNA, which has a hairpin loop structure, and uses inherent microRNA (miRNA) machinery to silence target gene expression. This is called RNA interference (RNAi). These can be delivered via plasmids or viral/bacterial vectors. Challenges in shRNA-mediated gene silencing include 1. Off-target silencing, 2. Packaging shRNA encoding lentivirus, and 3. Stable transduction in cells. RNAi has been designed to have anywhere from 19-27 bs, but the most effective design has 19 bp. In case commercial shRNAs are not available, potential target sites can be chosen within exon, 5’- or 3’ UTR, depending on which splice variants of the gene are desired. One should use the latest algorithms and choose at least two different sequences, targeting different regions, in order to have confidence in overcoming off-target effects. A BLAST search after selecting potential design will eliminate potential off-target sequences. For the second challenge, sequencing the vector using primers for either strand (50-100 bp upstream) is suggested, along with using enzymatic digestion on agarose gel for the vector. Next, once the shRNA-containing vector is packaged in a virus, it is important to check the viral titer before transduction. Finally, using a marker in the lentiviral vector (fluorescent protein or antibiotic resistance), along with qPCR for target gene expression can help in determining the efficacy of transduction and shRNA on its target site.